108 related articles for article (PubMed ID: 29467958)
1. Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study.
Hartimath SV; Manuelli V; Zijlma R; Signore A; Nayak TK; Freimoser-Grundschober A; Klein C; Dierckx RAJO; de Vries EFJ
Oncotarget; 2018 Jan; 9(6):7162-7174. PubMed ID: 29467958
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic modelling of N-(4-[(18)F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation.
Di Gialleonardo V; Signore A; Willemsen AT; Sijbesma JW; Dierckx RA; de Vries EF
Eur J Nucl Med Mol Imaging; 2012 Oct; 39(10):1551-60. PubMed ID: 22777334
[TBL] [Abstract][Full Text] [Related]
3. Development and Evaluation of Interleukin-2-Derived Radiotracers for PET Imaging of T Cells in Mice.
van der Veen EL; Suurs FV; Cleeren F; Bormans G; Elsinga PH; Hospers GAP; Lub-de Hooge MN; de Vries EGE; de Vries EFJ; Antunes IF
J Nucl Med; 2020 Sep; 61(9):1355-1360. PubMed ID: 32111688
[TBL] [Abstract][Full Text] [Related]
4. N-(4-18F-fluorobenzoyl)interleukin-2 for PET of human-activated T lymphocytes.
Di Gialleonardo V; Signore A; Glaudemans AW; Dierckx RA; De Vries EF
J Nucl Med; 2012 May; 53(5):679-86. PubMed ID: 22499614
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy.
van de Donk PP; Wind TT; Hooiveld-Noeken JS; van der Veen EL; Glaudemans AWJM; Diepstra A; Jalving M; de Vries EGE; de Vries EFJ; Hospers GAP
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4369-4376. PubMed ID: 34076745
[TBL] [Abstract][Full Text] [Related]
6. Clinical-grade N-(4-[
van der Veen EL; Antunes IF; Maarsingh P; Hessels-Scheper J; Zijlma R; Boersma HH; Jorritsma-Smit A; Hospers GAP; de Vries EGE; Lub-de Hooge MN; de Vries EFJ
EJNMMI Radiopharm Chem; 2019 Jul; 4(1):15. PubMed ID: 31659562
[TBL] [Abstract][Full Text] [Related]
7. [
Viitanen R; Virtanen H; Liljenbäck H; Moisio O; Li XG; Nicolini V; Richard M; Klein C; Nayak T; Jalkanen S; Roivainen A
Front Immunol; 2022; 13():901693. PubMed ID: 35874707
[TBL] [Abstract][Full Text] [Related]
8. Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy.
Ribba B; Boetsch C; Nayak T; Grimm HP; Charo J; Evers S; Klein C; Tessier J; Charoin JE; Phipps A; Pisa P; Teichgräber V
Clin Cancer Res; 2018 Jul; 24(14):3325-3333. PubMed ID: 29463551
[No Abstract] [Full Text] [Related]
9.
van Brummelen EMJ; Huisman MC; de Wit-van der Veen LJ; Nayak TK; Stokkel MPM; Mulder ER; Hoekstra OS; Vugts DJ; Van Dongen GAMS; Verheul HM; Evers S; Tessier JJL; Saro J; Schellens JHM; Menke-van der Houven van Oordt CW
Oncotarget; 2018 May; 9(37):24737-24749. PubMed ID: 29872502
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation and Quantification of
Khanapur S; van Waarde A; Dierckx RA; Elsinga PH; Koole MJ
J Nucl Med; 2017 Mar; 58(3):466-472. PubMed ID: 27789720
[TBL] [Abstract][Full Text] [Related]
11. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
[TBL] [Abstract][Full Text] [Related]
12. Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog.
Cheng Z; Zhang L; Graves E; Xiong Z; Dandekar M; Chen X; Gambhir SS
J Nucl Med; 2007 Jun; 48(6):987-94. PubMed ID: 17504880
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Contribution of IL2Rγ to the Dynamic Formation of IL2-IL2R Complexes.
Ponce LF; García-Martínez K; León K
PLoS One; 2016; 11(5):e0155684. PubMed ID: 27195783
[TBL] [Abstract][Full Text] [Related]
14. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
Klein C; Waldhauer I; Nicolini VG; Freimoser-Grundschober A; Nayak T; Vugts DJ; Dunn C; Bolijn M; Benz J; Stihle M; Lang S; Roemmele M; Hofer T; van Puijenbroek E; Wittig D; Moser S; Ast O; Brünker P; Gorr IH; Neumann S; de Vera Mudry MC; Hinton H; Crameri F; Saro J; Evers S; Gerdes C; Bacac M; van Dongen G; Moessner E; Umaña P
Oncoimmunology; 2017; 6(3):e1277306. PubMed ID: 28405498
[TBL] [Abstract][Full Text] [Related]
15. Role of interleukin 2 receptor beta chain in initiating anti-CD3 and interleukin 2-induced proliferation of human resting T cells.
Moiré N; Calvo CF; Métivier D; Perrot JY; Vaquero C; Hatakeyama M; Senik A
Eur J Immunol; 1990 Sep; 20(9):1981-7. PubMed ID: 2145171
[TBL] [Abstract][Full Text] [Related]
16. First-in-human PET quantification study of cerebral α4β2* nicotinic acetylcholine receptors using the novel specific radioligand (-)-[(18)F]Flubatine.
Sabri O; Becker GA; Meyer PM; Hesse S; Wilke S; Graef S; Patt M; Luthardt J; Wagenknecht G; Hoepping A; Smits R; Franke A; Sattler B; Habermann B; Neuhaus P; Fischer S; Tiepolt S; Deuther-Conrad W; Barthel H; Schönknecht P; Brust P
Neuroimage; 2015 Sep; 118():199-208. PubMed ID: 26037057
[TBL] [Abstract][Full Text] [Related]
17. Combining computational and experimental biology to develop therapeutically valuable IL2 muteins.
León K; García-Martínez K; Carmenate T; Rojas G
Semin Oncol; 2018 Jan; 45(1-2):95-104. PubMed ID: 30318089
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 2 production and interleukin 2 receptor expression by human immature leukemic T cells.
Sahraoui Y; Allouche M; Ammar A; Spanakis E; Clemenceau C; Jasmin C; Perraki M; Varela-Millot C; Georgoulias V
Leukemia; 1992 Oct; 6(10):1025-35. PubMed ID: 1405755
[TBL] [Abstract][Full Text] [Related]
19. 99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study.
Signore A; Annovazzi A; Barone R; Bonanno E; D'Alessandria C; Chianelli M; Mather SJ; Bottoni U; Panetta C; Innocenzi D; Scopinaro F; Calvieri S
J Nucl Med; 2004 Oct; 45(10):1647-52. PubMed ID: 15471828
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies identify three epitope clusters on the mouse p55 subunit of the interleukin 2 receptor: relationship to the interleukin 2-binding site.
Moreau JL; Nabholz M; Diamantstein T; Malek T; Shevach E; Thèze J
Eur J Immunol; 1987 Jul; 17(7):929-35. PubMed ID: 2440696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
